Identity and synonyms
Identity follows the supplied name and synonyms; no additional identity description is supplied.
Synonyms: NMN
Nonpeptide agent · Cofactor, nucleoside or nucleotide
Detailed molecular class: Non-peptide nucleotide precursor
Supplied sequence or chemical reference
PubChem CID: 14180
Molecular formula: C11H15N2O8P
IUPAC: [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate
Source: PC-NMN
Database chemical reference; does not certify supplier vial, salt, isomer or formulation.
Mechanism
NAD biosynthetic precursor.
Evidence and critical reading
Reported scientific and empirical uses
Reported glycemic control · Mitochondrial research · Replacement and nutritional context
NAD+ precursor promoted for metabolism/longevity.
Human evidence
A trial in prediabetic women studied muscle insulin sensitivity; not proof of weight loss or longer life in the general population.
Preclinical evidence
Animal aging mechanisms do not establish clinical anti-aging treatment.
Critical reading and limitations
A short intervention in postmenopausal women with prediabetes improved muscle insulin sensitivity, not human longevity.
Evidence applies to the exact molecule, formulation, route, population and endpoint studied. Supplier identity, purity and clinical equivalence are unverified.
Source-specific regimens
Descriptive source observations, not individual recommendations.
Regulatory product labeling
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Human-study exposure
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Empirical handbook
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Regulation and safety
Jurisdiction-specific regulatory context
Jurisdiction-specific approval not verified in this card; do not infer global nonapproval.
Adverse effects and unknowns
Long-term, pregnancy and combination safety remain insufficient for generalized claims.
Do not extrapolate to injection, both sexes or other diseases; long-term safety needs its own data.
Contraindications
See supported safety statements and exact product label; a complete contraindication set has not been established for this catalog material.
A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.
Interactions
Only explicitly cited interactions may be asserted; unstudied combinations remain unknown, not interaction-free.
Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.
Studies and trials
Selected studies
PMID33888596 · Randomized controlled trial
Postmenopausal women with prediabetes.
10-week supplementation.
Improved muscle insulin sensitivity; did not measure longevity.
Trial product/population; does not authenticate supplier material or permit simple indirect comparisons.
Trials attributed in the package
NCT03151239 · Effect of "Nicotinamide Mononucleotide" (NMN) on Cardiometabolic FunctionRegistry status: CompletedLast update posted: July 14, 2021Query verification: October 16, 2026
Trial registration does not establish efficacy or validate commercial material.
Query candidates; attribution pending
nicotinamide mononucleotide · 32 unfiltered query results, not authenticated trials
Query verification: October 16, 2026
Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.
View trial registry queryNCT07144527 · Nicotinamide Mononucleotide Supplementation for Exercise Tolerance Improvement in Healthy Older AdultsRegistry status: RecruitingLast update posted: October 7, 2026Query verification: October 16, 2026
NCT06739720 · RCT of Efficacy and Safety of CP003 on CFS/ME or Post COVID-19 FatigueRegistry status: RecruitingLast update posted: September 21, 2026Query verification: October 16, 2026
NCT07013591 · Nicotinamide Mononucleotide in Patients Undergoing Cardiac SurgeryRegistry status: RecruitingLast update posted: September 21, 2026Query verification: October 16, 2026
Source issues and references
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- PC-NMN
PubChem nicotinamide mononucleotide (CID 14180)
October 16, 2026
- PMID33888596
Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women.
Yoshino M, Yoshino J, Kayser BD, Patti GJ, Franczyk MP, Mills KF, Sindelar M, Pietka T, Patterson BW, Imai SI, Klein S.
October 16, 2026